Shengke Pharmaceuticals is an international drug discovery engine focused on the discovery and development of targeted small molecule inhibitors, which could target cell cycle regulatory proteins, signal transduction networks as well as tumor microenvironment for the treatment of cancer and other diseases.

Through multi-level partnerships and collaborations with global academic groups and industry experts, we are creating open research environments and devoted to translating molecular insights into better medicines. We are advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications.

Our core team members have a proven track record of important roles in the design and discovery of clinical candidates for the treatment of cancer and CNS disease.